This low-priced micro-cap biotech has some gigantic upside potential. Cycleriaon Therapeutics Inc. (NASDAQ: CYCN) is a clinical-stage biopharmaceutical company engaged in the discovering, development and commercialization of medicines for serious central nervous system (CNS) diseases.
The company’s product candidates include CY6463, a CNS-penetrant, soluble guanylate cyclase stimulator that is in Phase 2 trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes and Alzheimer’s disease with vascular pathology. Its Olinciguat is an orally administered vascular soluble guanylate cyclase stimulator that is in Phase 2 studies for the treatment of sickle cell disease. Praliciguat is an orally administered systemic sGC stimulator that is in Phase 2 trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction.
Truist Securities started coverage with a massive $14 price target. The consensus target is much lower at $10.50, and shares closed trading on Friday at $2.88 apiece.
This company has therapies for autoimmune and inflammatory diseases. InflaRx N.V. (NASDAQ: IFRX) is a clinical-stage biopharmaceutical company that discovers and develops inhibitors using C5a technology, primarily in Germany and the United States. Its C5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases.
The company’s lead product candidate is IFX-1, an intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase 2b clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease. It aims to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease, and pyoderma gangrenosum, a chronic inflammatory skin disorder. It is also developing IFX-1 for the treatment of oncological diseases.
The company also develops IFX-2, which is in the pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. InflaRx has co-development agreement with Beijing Defengrei Biotechnology.
Raymond James recently raised the price objective to $14 from $10. The consensus price target is just $9.08. The stock was last seen Friday at $4.65 a share.
Sponsored: Find a Qualified Financial Advisor
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.